OKYO Pharma Advances Urcosimod With Positive Interim Results and FDA Alignment on Phase 2b/3 NCP Trial

An announcement from OKYO Pharma Limited Sponsored ADR ( (OKYO) ) is now available.

On January 30, 2026, OKYO Pharma reported interim results for the six months ended September 30, 2025, highlighting a series of clinical, regulatory and financial milestones that advance its lead drug urcosimod for neuropathic corneal pain. Over the period, the company generated positive long-term stability data for urcosimod, secured FDA Fast Track Designation for its use in NCP, and reported strong topline Phase 2 proof‑of‑concept data in 18 patients, with 75% of per‑protocol participants achieving more than 80% pain reduction on the Visual Analogue Scale after 12 weeks, while also outlining a registration strategy that includes a planned 150‑patient multicenter Phase 2b/3 trial. OKYO supplemented this clinical progress with $1.9 million in non‑dilutive funding in July 2025 and improved its balance sheet to $4.2 million in cash and $4.6 million in total assets as of the period end, while narrowing its comprehensive loss to $3.0 million from $3.2 million a year earlier. In early 2026 the company further strengthened its leadership and regulatory position by appointing ophthalmology industry veteran Robert J. Dempsey as chief executive officer, transitioning former CEO Gary S. Jacob to chief development officer, and securing FDA alignment in a January 28, 2026 Type C meeting on the design, endpoints, and chemistry, manufacturing and controls strategy for the planned Phase 2b/3 urcosimod trial, in a move that de‑risks its pivotal program and positions OKYO as an emerging player in addressing a major unmet need in ophthalmology.

The most recent analyst rating on (OKYO) stock is a Hold with a $2.00 price target. To see the full list of analyst forecasts on OKYO Pharma Limited Sponsored ADR stock, see the OKYO Stock Forecast page.

Spark’s Take on OKYO Stock

According to Spark, TipRanks’ AI Analyst, OKYO is a Neutral.

The score is held down primarily by weak fundamentals (pre-revenue, ongoing losses, negative free cash flow, and negative equity) despite improved 2025 cost and cash-burn trends and zero debt. Technicals are a meaningful offset with strong momentum above key moving averages, while valuation remains challenged due to negative earnings and no indicated dividend yield.

To see Spark’s full report on OKYO stock, click here.

More about OKYO Pharma Limited Sponsored ADR

OKYO Pharma Limited is a clinical-stage biopharmaceutical company listed on the Nasdaq Capital Market, focused on developing innovative therapies for neuropathic corneal pain (NCP) and other inflammatory eye diseases. Its lead candidate, urcosimod, recently completed a successful Phase 2 trial in NCP, a debilitating ocular condition with no FDA-approved treatments, and the company is concentrating its pipeline and resources on advancing this asset through late-stage development.

Average Trading Volume: 192,891

Technical Sentiment Signal: Hold

Current Market Cap: $82.37M

Find detailed analytics on OKYO stock on TipRanks’ Stock Analysis page.